JP2017525777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525777A5 JP2017525777A5 JP2017530962A JP2017530962A JP2017525777A5 JP 2017525777 A5 JP2017525777 A5 JP 2017525777A5 JP 2017530962 A JP2017530962 A JP 2017530962A JP 2017530962 A JP2017530962 A JP 2017530962A JP 2017525777 A5 JP2017525777 A5 JP 2017525777A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- subject
- alkyl
- compound according
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 8
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- -1 pyrazolyl ethyl Chemical group 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- XTNOEYFQXCQKLC-UHFFFAOYSA-N 18-(oxiren-2-yl)octadeca-15,17-dienoic acid Chemical compound C1=C(C=CC=CCCCCCCCCCCCCCC(=O)O)O1 XTNOEYFQXCQKLC-UHFFFAOYSA-N 0.000 claims 2
- AVUQWNIWFSWLIY-UHFFFAOYSA-N 2,3-dihydroxyicosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCCC=CC=CC(O)=C(O)C(O)=O AVUQWNIWFSWLIY-UHFFFAOYSA-N 0.000 claims 2
- 108020002908 Epoxide hydrolase Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043275P | 2014-08-28 | 2014-08-28 | |
| US62/043,275 | 2014-08-28 | ||
| PCT/US2015/046878 WO2016033150A1 (en) | 2014-08-28 | 2015-08-26 | Soluble epoxide hydrolase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017525777A JP2017525777A (ja) | 2017-09-07 |
| JP2017525777A5 true JP2017525777A5 (OSRAM) | 2018-09-27 |
Family
ID=55400481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530962A Pending JP2017525777A (ja) | 2014-08-28 | 2015-08-26 | 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10081616B2 (OSRAM) |
| EP (1) | EP3186228A4 (OSRAM) |
| JP (1) | JP2017525777A (OSRAM) |
| CN (2) | CN111454246A (OSRAM) |
| AU (2) | AU2015306643B2 (OSRAM) |
| CA (1) | CA2958881A1 (OSRAM) |
| MA (1) | MA40538A (OSRAM) |
| WO (1) | WO2016033150A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40538A (fr) * | 2014-08-28 | 2021-04-07 | X Chem Inc | Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci |
| EP3600266B1 (en) * | 2017-03-30 | 2022-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for use in the treatment of cardiovascular calcification |
| US20230071934A1 (en) * | 2019-12-18 | 2023-03-09 | Intra-Cellular Therapies, Inc. | Novel uses |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3245950A1 (de) * | 1981-12-24 | 1983-07-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur herstellung substituierter pyridine |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| EP1987004A2 (en) * | 2006-02-16 | 2008-11-05 | Boehringer Ingelheim International GmbH | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| WO2007106705A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| CN101522614B (zh) * | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| JP2010513458A (ja) * | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| US20110039860A1 (en) * | 2008-05-07 | 2011-02-17 | Cangming Yang | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| WO2009153720A1 (en) * | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| US20110306597A1 (en) * | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| US20100113512A1 (en) * | 2008-10-30 | 2010-05-06 | Diane Michele Ignar | Method of treatment using novel antagonists or inverse agonists at opioid receptors |
| WO2010080183A1 (en) | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| WO2011091410A1 (en) * | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Trpv4 antagonists |
| US20130102600A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US20130102601A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| CN104136028A (zh) * | 2012-01-25 | 2014-11-05 | 纽约市哥伦比亚大学理事会 | 高效可溶性环氧化物水解酶非脲抑制剂 |
| MX2015006037A (es) * | 2012-11-16 | 2015-08-07 | Merck Patent Gmbh | Derivados de 3-aminociclopentancarboxamida. |
| CN104016914B (zh) * | 2014-05-27 | 2016-03-30 | 苏州科技学院 | 一种酰胺化合物的制备方法 |
| MA40538A (fr) * | 2014-08-28 | 2021-04-07 | X Chem Inc | Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci |
-
2015
- 2015-08-26 MA MA040538A patent/MA40538A/fr unknown
- 2015-08-26 WO PCT/US2015/046878 patent/WO2016033150A1/en not_active Ceased
- 2015-08-26 US US15/504,223 patent/US10081616B2/en not_active Expired - Fee Related
- 2015-08-26 CN CN202010138750.0A patent/CN111454246A/zh active Pending
- 2015-08-26 JP JP2017530962A patent/JP2017525777A/ja active Pending
- 2015-08-26 CN CN201580046202.2A patent/CN107074771B/zh not_active Expired - Fee Related
- 2015-08-26 EP EP15837061.9A patent/EP3186228A4/en not_active Withdrawn
- 2015-08-26 AU AU2015306643A patent/AU2015306643B2/en not_active Ceased
- 2015-08-26 CA CA2958881A patent/CA2958881A1/en not_active Abandoned
-
2018
- 2018-08-23 US US16/110,698 patent/US20180362499A1/en not_active Abandoned
-
2020
- 2020-07-22 AU AU2020207828A patent/AU2020207828A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| JP2016533366A5 (OSRAM) | ||
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| JP2016506916A5 (OSRAM) | ||
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| JP2016534063A5 (OSRAM) | ||
| JP2016506935A5 (OSRAM) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| MX2009001534A (es) | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. | |
| JP2016510326A5 (OSRAM) | ||
| RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
| JP2013522326A5 (OSRAM) | ||
| JP2017514910A5 (OSRAM) | ||
| JP2015524807A5 (OSRAM) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| NZ608584A (en) | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations | |
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| IN2014DN08582A (OSRAM) | ||
| EA022018B1 (ru) | Кристаллические оксалатные соли диамидного соединения | |
| JP2017519020A5 (OSRAM) | ||
| JP2019516707A5 (OSRAM) | ||
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension |